Another Sea Change In Myeloma Promised By New Therapies, Combos

Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation anti-CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.